CEBPB and lung carcinoma: Consistent the results of Figure 1B, as shown in Figures 2A, B, SNAI1 (n=10; 100%), CCN1 (n=11; 81.8%), CEBPB (n=12; 86.7%), CDKN1A (n=12; 58.3%) were upregulated in lung cancer, while SOX2 (n=12; 41.7%), PDCD10 (n=11; 36.4%), SIX1 (n=12; 86.7%) and MDH1 (n=11; 18.2%) were downregulated in lung cancer.